# Safety and Tolerability of IBI355 in Healthy Volunteers

> **NCT06416787** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** placebo
- **DRUG:** IBI355

## Key facts

- **NCT ID:** NCT06416787
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-20
- **Primary completion:** 2025-02-26
- **Final completion:** 2025-04-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06416787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06416787, "Safety and Tolerability of IBI355 in Healthy Volunteers". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06416787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*